Just a few months after doing a string of RNA deals with J&J, CureVac and others in the wake of a reverse merger onto Nasdaq, Arcturus $ARCT CEO Joseph Payne is out.
In a statement out this morning the company said that the board had decided to terminate Payne, going only so far as to rule out operational performance, ongoing programs, financial condition or financial reporting as causes.
BD chief Mark Herbert has been named interim president until a permanent replacement is found.
“Mark is a seasoned biotechnology leader who has gained a deep understanding of our strategy, business and partnerships since joining the company in 2015,” said Stuart Collinson, the executive chairman of the Arcturus board. “We are confident that Mark, working with me, the board and the management team, will help us to achieve our objective of developing innovative RNA medicines with the potential to transform the lives of patients with serious diseases.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,700+ biopharma pros who read Endpoints News by email every day.Free Subscription